Alipogene tiparvovec
Top View
- 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- Rare Dyslipidaemias, from Phenotype to Genotype to Management: a European Atherosclerosis Society Task Force Consensus Statement
- Glybera, INN-Alipogene Tiparvovec
- Decade in Review—Dyslipidaemia: Resurgence of Targets And
- Emerging Strategies of Targeting Lipoprotein Lipase for Metabolic and Cardiovascular Diseases
- Biosimilar Product Differences Will Affect US Uptake, Amgen Predicts
- Literature Update Week 05 (2019) [1] Cardellini M, Rovella V, Scimeca M
- Alipogene Tiparvovec: Gene Therapy for Lipoprotein Lipase Deficiency
- Glybera, INN-Alipogene Tiparvovec
- WHO Prequalification of Medicines
- Agenda of PDCO Meeting of 27-29 January 2016
- Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark∗
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Suggested Reading List
- Regulatory Change in Pharmaceutical Price: Evidence from A
- Complex Dyslipidemias: Challenges in Management
- FDA Briefing Document Endocrinologic and Metabolic